HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Industry Group Commits To Compliance With EU Novel Food Law

Executive Summary

Seeking to end the current impasse between regulators and the CBD industry, the Centre For Medicinal Cannabis is launching a quality charter for its members to put their products “on the path to regulatory compliance.” 

You may also be interested in...



Confusion Reigns In UK CBD Market As Regulatory Vacuum Allowed To Continue

Major retailers LloydsPharmacy and Holland & Barrett remain unfazed by the regulatory chaos surrounding cannabidiol (CBD) in the UK, while pharmacy groups become increasingly concerned that their members may be selling controlled substances due to the possible presence of tetrahydrocannabinol (THC).

UK Body Calls For 'Clear Guidance' On THC Levels In CBD Oils

UK's Royal Pharmaceutical Society calls on government to clarify permissible THC levels in CBD oils to avoid pharmacists selling illegal products. 

Cannabis Trade Group Threatens FSA With Legal Action As CBD Novel Food Row Intensifies

Cannabis trade association CannaPro is threatening legal action against the UK's Food Standards Agency for its response to moves by EU regulators to classify CBD as a novel Food. The FSA's handling of the situation is negatively impacting business, states CannaPro, which has warned the agency it will sue for damages.  

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel